Since then, other approved antitumor applications for IFN-α2a or IFN-α2b include AIDS-related Kaposi's sarcoma, chronic myelogenous leukemia, follicular lymphoma, and malignant melanoma [6]. Here, IFNA2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.